readthroughSign in
Nov 10, 2026Financing

ABVC Biopharma raises $3.39 million through convertible note private placement

The Nevada biotech reported a Form D filing for senior convertible promissory notes sold to nine investors with a first sale date of October 30, 2026.

ABVC Biopharma, Inc., based in Fremont, California, filed a Form D with the SEC disclosing a private securities offering with a first sale date of 2026-10-301.

The filing states that the amounts reported reflect the aggregate purchase price of $3,387,500 paid for senior convertible promissory notes with an aggregate principal amount of $4,106,060, issued at a 17.5% original issue discount.1 The total offering amount and total amount sold were both listed as $3,387,500, with Total Remaining to be Sold1 at $0.

The offering was sold under Rule 506(b)1 of Regulation D. The company reported a total of 9 investors who already have invested in the offering1, and set a minimum investment of $125,0001 for any outside investor.

The filing names WallachBeth Capital, LLC as the exclusive placement agent for the private placement, with the company paying a cash fee equal to 7% of gross proceeds plus reimbursement of accountable expenses of $65,0001, with total sales commissions listed at $237,125. The filing states no proceeds were directed to executive officers, directors or promoters1 listed in the related persons section, and that the offering is not connected to a business combination transaction, such as a merger, acquisition or exchange offer1.

The filing lists executive officers and directors including Uttam Patil, Eugene Jiang, and Tsung-Shann Jiang, among others, all associated with the company's address at 44370 Old Warm Springs Blvd, Fremont, California. The notice was signed by Uttam Patil, identified as Chief Executive Officer, on 2026-11-101.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.